One Formulation. Multiple Doses. Faster Development.

Multiparticulate systems are increasingly changing the way pharmaceutical companies approach early drug product development. While conventional monolithic dosage forms such as tablets remain the industry standard for many commercial products, they often become a limiting factor during dose finding studies where flexibility and speed are essential.

In early clinical development, dose requirements rarely remain fixed. Pharmacokinetic and pharmacodynamic data emerging from Phase I and Phase II studies frequently require rapid dose adjustments. Moving from 5 mg to 20 mg or from 20 mg to 80 mg may appear straightforward from a clinical perspective, but for traditional tablet formulations, these changes can trigger extensive additional development work.

A monolithic tablet is a single integrated system.

Any significant dose change often affects tablet size, excipient ratios, compression behavior, dissolution performance, and manufacturability. In practice, each strength may require its own formulation optimization and process evaluation. This immediately creates additional analytical work, scale up considerations, and new stability studies.

The result is a familiar challenge for development teams: valuable time is lost waiting for reformulation activities and stability data before the next clinical step can begin.

Multiparticulates offer a fundamentally different approach.

Instead of relying on a single compressed unit, multiparticulate systems use hundreds or thousands of pellets filled into capsules or sachets. The formulation itself remains unchanged while the dose is adjusted simply by modifying the filling weight of pellets inside the capsule.

A lower dose may contain only a small quantity of pellets, while a higher dose uses the exact same pellets at a greater fill weight.

This simple concept creates enormous advantages during dose finding.

Because the pellet formulation does not change, stability data generated for one strength can often support an entire dose range. Development teams avoid the repeated cycle of reformulation, analytical verification, and long term stability studies that commonly slows monolithic systems.

In practical terms, this means clinical programs can progress faster and with significantly lower technical risk.

The benefits become particularly important in therapeutic areas where dosing strategies evolve continuously. Oncology, pediatric formulations, central nervous system therapies, and highly potent compounds frequently require dose escalation, titration, or individualized dosing approaches. Multiparticulates allow these adjustments without redesigning the dosage form each time new clinical insights emerge.

The technical robustness of pellet systems is another important advantage.

Traditional tablets are highly sensitive to formulation changes. Even relatively minor modifications in excipient concentration or compression parameters can alter dissolution behavior and bioavailability. Each reformulation therefore introduces uncertainty precisely when development programs need consistency and predictability.

Multiparticulates separate dose adjustment from formulation redesign. The same pellet population maintains consistent release characteristics across multiple strengths, allowing developers to focus on clinical outcomes rather than repeatedly solving formulation challenges.

Many multiparticulate technologies also enable advanced release profile design. Immediate release and modified release pellets can be combined within the same capsule, creating flexible pharmacokinetic profiles while maintaining a single platform formulation.

Beyond development efficiency, multiparticulates can also improve clinical performance. The small pellet units distribute more uniformly throughout the gastrointestinal tract, often leading to more reproducible absorption and reduced variability between patients. They may also reduce the risk of localized irritation and minimize the potential for dose dumping compared with single unit systems.

For pharmaceutical developers, the strategic value is increasingly clear.

Multiparticulates support a “develop once and adapt continuously” philosophy. Instead of repeatedly reformulating products for every new dose level, companies can build a stable platform early in development and adjust doses rapidly as clinical knowledge evolves.

In an industry where development timelines directly influence both cost and competitive advantage, avoiding months of additional stability work is not merely a technical benefit. It is a critical acceleration strategy for modern drug development.

What is your take on it other than the standard one “to complex for early development” and only for “line extension”. Isn´t it time to rethink and go for a potential platform approach which can save time & money down the road? In best case we can go from IR to extended release at different drug levels with one basis.

Thanks for entering the discussion with the multiparticulate experts from Glatt Pharmaceutical Services – CDMO Unlimited for further information.

See Philippe Tschopp´s original LinkedIn post here

Source: Philippe Tschopp, Glatt, LinkedIn, One Formulation. Multiple Doses. Faster Development. | LinkedIn